Demyelinating events in rheumatoid arthritis after drug exposures

Annals of the Rheumatic Diseases

Volumn 69, Issue 9, 2010, Pages 1691-1693

  Bernatsky, Sasha ^a,b   Renoux, Christel ^c   Suissa, Samy ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG EXPOSURE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; OPTIC NEURITIS; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; CASE-CONTROL STUDIES; DEMYELINATING DISEASES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956021184     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.111500     Document Type: Article

References (11)

1. Toussirot E, Pertuiset E, Martin A, et al. Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol 2006;33:1027-8.
2. Attout H, Toussirot E, Augé B, et al. Rheumatoid arthritis and multiple sclerosis in the same patient. Two case-reports. Rev Rhum Engl Ed 1999;66:169-72.
3. Bensouda-Grimaldi L, Mulleman D, Valat JP, et al. Adalimumab-associated multiple sclerosis. J Rheumatol 2007;34:239-40; discussion 240.
4. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.
5. Do HH, Mohamed A, Klistorner A, et al. Ophthalmic manifestations of demyelination secondary to etanercept. Clin Exp Ophthalmol 2008;36:392-4. (Pubitemid 352015187)
6. Kameda T, Dobashi H, Kittaka K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol 2008;18:399-402.
7. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008;168:378-81.
8. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64.
9. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93.
10. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
11. Warren SA, Svenson LW, Warren KG. Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler 2008;14:872-9.